Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Monday, April 11, 2022
Robert B. Campbell, PhD, of the Massachusetts College of Pharmacy and Health Sciences, Worcester, and colleagues developed and evaluated cell membrane lipid–extracted nanoliposomes (CLENs) as a possible therapeutic platform for targeting multiple myeloma. CLENs, a type of nanoparticle, are a drug delivery approach that may offer more selective uptake while minimizing the toxicity associated with treatment. Their research was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract 237/3).
The investigators selected the RPMI-8226 multiple myeloma cell line as a cellular model for multiple myeloma. Through physicochemical and in vitro studies, they identified the optimal preparation of the RPMI-8226 CLENs to contain 90% 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 5% RPMI-8226 lipid extraction, and 5% cholesterol. The addition of RPMI-8226 lipid extraction in conventional DOPC plus cholesterol liposomes resulted in “significantly improved” uptake of the CLENs by RPMI-8226 cells in vitro (P < .001).
However, preliminary selectivity studies indicated no significant difference in the uptake of RPMI-8226 CLENs by RPMI-8226 when compared with control cell lines from other hematologic diseases, including chronic myeloid leukemia (K-562-GFP), acute lymphoblastic leukemia (CCRF-CEM), and lymphoma (U937). Further studies are currently underway to investigate target selectivity and the inclusion of additional components of CLENs as a function of the microenvironment.
Disclosure: The study authors reported no conflicts of interest.
